|
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes |
Oct 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
